These two Houston software companies are making contracts less cumbersome for oil and gas companies

Team work

James Yockey is a co-founder of Landdox, which recently integrated with ThoughtTrace. Courtesy of Landdox

The biggest asset of most oil and gas companies is their leasehold: the contracts or deeds that give the company the right to either drill wells and produce oil and gas on someone else's land, or give them title to that land outright. A typical oil and gas company is involved in thousands of these uniquely negotiated leases, and the software to keep these documents organized hasn't been updated in more than a decade, says James Yockey, founder of Houston-based Landdox.

Landdox does just that: provides an organizational framework for companies' contracts and leaseholds. The company recently entered into an integration with Houston-based ThoughtTrace, an artificial intelligence program that can scan and pull out key words and provisions from cumbersome, complicated contracts and leaseholds.

With this integration, companies can use ThoughtTrace to easily identify key provisions of their contracts, and then sync up those provisions with their Landdox account. From there, Landdox will organize those provisions into easy-to-use tools like calendars, reminders and more.

The framework behind the integration
The concept behind Landdox isn't entirely new — there are other software platforms built to organize oil and gas company's assets — but it's the first company in this space that's completely cloud-based, Yockey says.

"Within these oil and gas leases and other contracts are really sticky provisions … if you don't understand them, and you're not managing them, it can cause you to forfeit a huge part of your asset base," Yockey says. "It can be a seven-, eight-, or nine-digit loss."

These contracts and leases can be as long as 70 or 80 pages, Yockey says, and have tricky provisions buried in them. Before the integration with ThoughtTrace, oil and gas companies would still have to manually pour over these contracts and identify key provisions that could then be sent over to Landdox, which would organize the data and documents in an easy-to-use platform. The ThoughtTrace integration removes a time-consuming aspect of the process for oil and gas companies.

"[ThoughtTrace] identifies the most needle moving provisions and obligations and terms that get embedded in these contracts by mineral owners," Yockey says. "It's a real source of leverage for the oil and gas companies. You can feed ThoughtTrace the PDF of the lease and their software will show you were these provisions are buried."

The origin story
Landdox was founded in 2015, and is backed by a small group of angel investors. Yockey says the investors provided a "little backing," and added that Landdox is a "very capital-efficient" software company.

Landdox and ThoughtTrace connected in 2017, when the companies were working with a large, private oil and gas company in Austin. The Austin-based oil and gas company opted to use Landdox and ThoughtTrace in parallel, which inspired the two companies to develop an integrated prototype.

"We built a prototype, but it was clear that there was a bigger opportunity to make this even easier," Yockey says. "To quote the CEO of ThoughtTrace, he called [the integration] an 'easy button.'"

The future of ERP software
Landdox's average customer is a private equity-backed E&P or mineral fund, Yockey says, thought the company also works with closely held, family-owned companies. Recently, though, Landdox has been adding a new kind of company to its client base.

"What's interesting is we're starting to add a new customer persona," Yockey says. "The bigger companies – the publicly traded oil and gas companies –have all kinds of different ERP (Enterprise Resource Planning) software running their business, but leave a lot to be desired in terms of what their team really needs."

At a recent North American Prospect Expo summit, Yockey says that half a dozen large capitalization oil and gas producers invited Landdox to their offices, to discuss potentially supplementing the company's ERP software.

"Instead of trying to be all things to all people, we stay in our lane, but find cool ways to connect with other software (companies)," Yockey says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

  • Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
  • Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
  • Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
  • Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

  • Energy systems such as nuclear and geothermal
  • Energy supply chains
  • Energy-transition fuel and technology
  • Traditional energy
“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

View All Listings